ValGenesis Inc, a company involved in Enterprise Validation Lifecycle Management Solutions, has named Dr Ajaz Hussain as a member of its board of directors and chairman of its advisory board from 8 September 2017, it was reported yesterday.

Dr Ajaz Hussain brings a range of international pharmaceutical regulatory and business experience to ValGenesis, including his decade-long tenure with the United States Food and Drug Administration (US FDA), Center for Drug Evaluation and Research (CDER). He has led some of the US FDA's major initiatives to develop regulatory policies that already have and are likely to continue to have a significant impact on product development and approval in many geographies. The US FDA has honoured him on multiple occasions for his outstanding contributions and innovative scientific approach to resolve complex regulatory and compliance challenges. He also currently serves as the president of The National Institute for Pharmaceutical Technology and Education, a not-for-profit educational organisation, which is a collaboration of 17 major universities in the US. Grants from US FDA primarily fund the research and training programs.

Dr Siva Samy, CEO & chief product strategist for ValGenesis Inc, said, 'ValGenesis is excited to have Dr Ajaz Hussain on its board and as the chairman of the advisory board. Dr Ajaz Hussain is one of the architects for science-based approaches to quality and compliance at FDA. His expertise and experience as deputy director of FDA and as a life sciences commercial executive will help to evolve ValGenesis VLMS on par with evolving regulatory requirements and industry needs. ValGenesis VLMS has been implemented as system records for validation process by top 10 out of 20 global life science companies. We have increased responsibility to align our product roadmap with evolving regulatory landscape to help our clients to enable/enforce the current regulatory requirements. We firmly believe that this collaboration will help ValGenesis VLMS become a de-facto standard on how Validation Lifecycle should be assured and managed across the global life science companies.'